德琪医药-B 港股通 空最新增减持 (2026-03-24) 官网 ( 06996.hk) | -12.33 | 4.59 | 0% | 上市时间2020-11-20股价4.83港币涨跌幅2.77%成交金额1,572.37万港币换手率0.48%市值32.82亿港币H股市值32.82亿港币总股本6.79亿H股本6.79亿每手股数500上市至今年化投资收益率-21.87%港股通持仓占H股比例1.41% (4,468.42万港币2026-03-25) 累计做空占H股比例1.50% (4,132.86万港币2026-03-20) | |||
| 所属三级行业药品 (恒生) | 市盈率 | 29.76 | 市净率 | 2.82 | 股息率 | 1.35% | 恒生:医疗保健业药品及生物科技药品 |
| 备注 (1): | 双击编辑备注 |
德琪医药-B(06996) - 历史董事名单
| # | 姓名 | 职衔 | 职位 | 委任日期 | 辞任日期 |
|---|---|---|---|---|---|
| 1 | FONSECA Rafael | Independent Non Executive Director | 2023-04-14 | -- | |
| 2 | 劉逸倫 | Non Executive Director | 2021-12-16 | 2023-04-14 | |
| 3 | 龍振國 | Executive Director | 2021-06-18 | -- | |
| 4 | LYNCH Kevin Patrick | Executive Director | 2021-06-18 | 2022-12-16 | |
| 5 | 陳侃 | Non Executive Director | 2021-03-26 | -- | |
| 6 | 錢晶 | Independent Non Executive Director | 2020-11-09 | -- | |
| 7 | 唐晟 | Independent Non Executive Director - A/F | 2020-11-09 | -- | |
| 8 | CHIN John Francis | Executive Director | 2020-08-18 | -- | |
| 9 | ALLES Mark John | Independent Non Executive Director | 2020-01-02 | 2023-04-14 | |
| 10 | 曹彥凌 | Non Executive Director | 2019-02-04 | 2021-12-16 | |
| 11 | 李甄 | Non Executive Director | 2019-02-04 | 2021-06-18 | |
| 12 | 劉翼騰 | Executive Director | 2018-11-22 | 2021-06-18 | |
| 13 | 胡旭波 | Non Executive Director | 2018-11-22 | 2021-03-26 | |
| 14 | 梅建明 | Executive Director | Chairman, CEO | 2018-08-28 | -- |